» Articles » PMID: 31835765

Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value

Abstract

Background: Acute cardiac events are a significant contributor to mortality in systemic sclerosis (SSc). However, echocardiographic evaluation may be deceptively normal during an acute presentation. We hypothesized that in diffuse SSc patients presenting with acute cardiac events and a normal echocardiogram, cardiovascular magnetic resonance (CMR) would have incremental diagnostic/prognostic value.

Methods: 50 consecutive diffuse SSc patients with normal echocardiograms were evaluated using a 1.5T system. A total of 27 (63%) had experienced an acute cardiac event three to tendays before CMR evaluation (rhythm disturbances, angina pectoris, shortness of breath). Left/right ventricular (LV/RV) volumes and ejection fractions (EF), as well as LV mass, the T2-signal ratio, early/late gadolinium enhancement (EGE/LGE), native/post-contrast T1-mapping, T2-mapping and extracellular volume fraction (ECV) were compared between the event and no-event groups.

Results: No differences were identified in LV/RV volumes/EF/mass. In logistic regression analyses, independent predictors of belonging to the event group were EGE (odds ratio (95% CI): 1.55 (1.06-2.26), = 0.024), LGE (1.81 (1.23-2.67), = 0.003), T2 mapping (1.20 (1.06-1.36), = 0.004) and native/post-contrast T1 mapping (1.17 (1.04-1.32), = 0.007 and 0.86 (0.75-0.98), = 0.025). At a median follow-up of ~1.2 years, 42% vs. 11% of the event/no-event group respectively reached a combined endpoint of event occurrence/recurrence or cardiovascular mortality. Of the independent predictors resulting from logistic regression analyses, only LGE (hazard ratio (95% CI): 1.20 (1.11-1.30), < 0.001), T2-mapping (1.07 (1.01-1.14), = 0.025) and native T1-mapping (1.08 (1.01-1.15), = 0.017) independently predicted the combined endpoint.

Conclusions: A normal echocardiogram does not preclude myocardial lesions in diffuse SSc patients, which can be detected by CMR especially in symptomatic patients.

Citing Articles

Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution.

Fairley J, ORourke R, Puranik R, Nikpour M Rheumatol Immunol Res. 2024; 5(2):83-92.

PMID: 39015845 PMC: 11248552. DOI: 10.1515/rir-2024-0011.


Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment.

Bruni C, Buch M, Djokovic A, Luca G, Dumitru R, Giollo A J Scleroderma Relat Disord. 2023; 8(3):169-182.

PMID: 37744047 PMC: 10515996. DOI: 10.1177/23971983231163413.


The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement.

He H, Lai J, Zhou J, Hou Y, Xu D, Li M Orphanet J Rare Dis. 2023; 18(1):83.

PMID: 37060032 PMC: 10103520. DOI: 10.1186/s13023-023-02699-1.


Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.

Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M Front Immunol. 2023; 13:974078.

PMID: 36776390 PMC: 9910219. DOI: 10.3389/fimmu.2022.974078.


The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.

Bratoiu I, Burlui A, Cardoneanu A, Macovei L, Richter P, Rusu-Zota G Int J Mol Sci. 2022; 23(19).

PMID: 36233313 PMC: 9569846. DOI: 10.3390/ijms231912011.


References
1.
Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M . Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum. 2013; 43(4):526-35. DOI: 10.1016/j.semarthrit.2013.07.006. View

2.
Friedrich M, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper L . Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009; 53(17):1475-87. PMC: 2743893. DOI: 10.1016/j.jacc.2009.02.007. View

3.
Barnes J, Mayes M . Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012; 24(2):165-70. DOI: 10.1097/BOR.0b013e32834ff2e8. View

4.
Arias-Nunez M, Llorca J, Vazquez-Rodriguez T, Gomez-Acebo I, Miranda-Filloy J, Martin J . Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore). 2008; 87(5):272-280. DOI: 10.1097/MD.0b013e318189372f. View

5.
Al-Dhaher F, Pope J, Ouimet J . Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2008; 39(4):269-77. DOI: 10.1016/j.semarthrit.2008.06.002. View